A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

NCT06075095 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

297

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD (Chronic Obstructive Pulmonary Disease)

Interventions

DRUG: BGF MDI HFO 320/14.4/9.6μg
DRUG: BGF MDI HFA 320/14.4/9.6 μg
DRUG: Placebo MDI HFA

Sponsor

AstraZeneca